CM
ESPR

Crestline Management’s Esperion Therapeutics ESPR Stock Holding History

Crestline Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,745
Closed -$63.2K – 208
2024
Q4 		$63.2K Buy
+28,745
New +$67.1K ﹤0.01% 703
2018
Q3 		– Sell
-44,224
Closed -$1.73M – 175
2018
Q2 		$1.73M Buy
+44,224
New +$2.23M 0.18% 157
2017
Q4 		– Sell
-26,350
Closed -$1.32M – 173
2017
Q3 		$1.32M Sell
26,350
-14,616
-36% -$705K 0.18% 89
2017
Q2 		$1.9M Buy
40,966
+13,566
+50% +$499K 0.25% 45
2017
Q1 		$967K Buy
+27,400
New +$627K 0.18% 55

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return